NCT01338896 is a Phase 1 clinical trial of Rotigotine transdermal patch in Parkinson's Disease, sponsored by UCB Pharma.

Who is sponsoring NCT01338896?

NCT01338896 is sponsored by UCB Pharma.

What drugs are being tested in NCT01338896?

Interventions in NCT01338896: Rotigotine transdermal patch.

What condition does NCT01338896 study?

NCT01338896 studies Parkinson's Disease.

Is NCT01338896 still recruiting?

NCT01338896 is currently completed. Last updated 26 August 2011.

Last reviewed 2011-08-26 · How we verify

NCT01338896

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Randomized, Double-blind, Two-way Cross-over Study to Compare the Adhesiveness of Two Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease

Completed Phase 1 Last updated 26 August 2011

What this trial tests

Phase 1 trial testing Rotigotine transdermal patch in Parkinson's Disease in 56 participants. Completed in 1 June 2011.

Timeline

1 April 2011

Primary endpoint
1 May 2011

1 June 2011

Quick facts

Lead sponsor	UCB Pharma
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	56
Start date	1 April 2011
Primary completion	1 May 2011
Estimated completion	1 June 2011
Sites	16 locations across Austria, Germany, United Kingdom

Drugs / interventions tested

Rotigotine transdermal patch — full drug profile →

Conditions studied

Parkinson's Disease — all drugs for Parkinson's Disease →

Sponsor

UCB Pharma — full company profile →

Who can join

18 and older, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The average adhesiveness score of 2 days of 24 hours patch application as rated by the investigator (or designee)
Time frame: 2 days of 24 hours patch application
The international patch adhesiveness score

Sponsor's own description

The primary objective of the study is to compare the adhesiveness of two different patch formulations of rotigotine using patch size 40 cm2, under the assumption that both patch formulations show similar adhesiveness properties.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations.
Elshoff JP, Timmermann L, Schmid M, Arth C, et al · · 2013 · cited 8× · PMID 24006953 · DOI 10.1185/03007995.2013.841666

Verify or expand the search:

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting

Other UCB Pharma trials

Trials by the same sponsor.

NCT01969851 — A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Mo · Phase 2 · completed
NCT01921205 — Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures · Phase 3 · completed
NCT01095393 — National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cim · completed
NCT00350103 — A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy · Phase 3 · completed
NCT00291668 — Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01338896 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UCB Pharma
Last refreshed: 26 August 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01338896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing